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The hepatitis C virus (HCV) is a major cause of chronic hepatitis,
cirrhosis and hepatocellular carcinoma worldwide. A signiﬁcant
portion of the morbidity and mortality associated with HCV is a
consequence of numerous HCV-associated comorbidities. Type
2 diabetes and atherosclerosis, two known complications of the
metabolic syndrome, are noteworthy, because HCV has been sug-
gested to play a role in their pathogenesis. In addition, HCV also
causes steatosis, which may increase the risk of cardiovascular
events. This review summarizes the evidence supporting the
association between HCV and steatosis, insulin resistance/type
2 diabetes and cardiovascular morbidity and mortality. Their
diagnostic, prognostic and management aspects are discussed.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
The hepatitis C virus (HCV) is a major cause of cirrhosis and hepa-
tocellular carcinoma worldwide. In a recent systematic literature
review, the global HCV prevalence was estimated to be 2.8% of
the world’s population, corresponding to 185,000,000 persons
infected [1]. The same study reported recently that in 2010 there
were approximately 10 times more deaths attributable to viral
hepatitis in the European Union than to human immunodeﬁ-
ciency virus (HIV), with two thirds of the viral hepatitis deaths
associated with HCV [2]. Similar data have been reported in the
USA, where HCV-associated mortalities surpassed those due toJournal of Hepatology 20
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motif] ligand 2; IFN, interferon; IMT, intima-media thickness.HIV in 2007 [3]. This already worrisome mortality rate is bound
to increase at least until 2030 [4], as complications of end stage
liver disease occur decades after infection, the vast majority of
which occurred in the 1960’s and 1970’s. This will impose a
signiﬁcant burden on the health care systems worldwide [5].
Although cost-effectiveness studies on measures aimed at bat-
tling the HCV epidemic have essentially focused on liver disorder-
related costs, a signiﬁcant portion of the health burden associated
with HCV is the consequence of a number of HCV-associated
comorbidities [6] (Fig. 1). Among these, type 2 diabetes and ath-
erosclerosis, two otherwise well-known, major complications of
the metabolic syndrome, are noteworthy, because HCV infection
has been linked to their pathogenesis [7]. In addition, HCV also
causes steatosis [8], which has been suggested to increase the risk
of cardiovascular morbidity [9]. This raises the legitimate ques-
tion as to whether the successful management of HCV may also
impact the future morbidity and mortality due to diabetes and
atherosclerosis. The scope of this review is to discuss some aspects
related to the epidemiology and pathogenesis of such manifesta-
tions, and to discuss their management.
Key Points
• Chronic hepatitis C patients often present with 
steatosis, which shows a strong genotype dependence, 
correlates with viral load, and disappears in case of 
successful therapy
• Viral steatosis is not associated with rapid fibrosis 
progression or poor response to IFN-α, but may be a 
risk factor for HCC
• HCV is associated with insulin resistance that may 
progress to type 2 diabetes in patients at risk, and 
leads to poor response to IFN-α, accelerated fibrosis 
progression and HCC
• HCV-infected persons are at higher risk of 
cardiovascular events, independently of other risk 
factors
• Successful antiviral therapy may reduce the risk of 
developing type 2 diabetes and ischaemic stroke14 vol. 61 j S69–S78
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Journal of Hepatology Update: Hepatitis CFig. 1. Hepatic and extrahepatic disorders associated with HCV infection.Steatosis
Evidence for a viral role in inducing fatty liver
Chronic HCV infection is associated with steatosis [8,10]. This is
suggested by the strong association of steatosis with HCV geno-
type 3: patients with this genotype have a 5-fold probability
of having moderate to severe steatosis, more than those with
non-3 genotypes [11], hinting at viral sequences responsible for
the fat accumulation. Occurrence and severity of steatosis in
patients with HCV genotype 3 correlates with the viral load and
the response to antivirals: fat accumulation disappears in patients
who reach a sustained virological response (SVR), and reappears
when infection relapses [12]. The dependence of HCV replication
and spread on the host lipid metabolism partly explains this close
association: (i) speciﬁc lipid species are essential for the HCV life
cycle, as their depletion inhibits viral replication; (ii) virion
assembly and egress depend on lipid droplets and exploit the
hepatocyte lipoprotein secretion pathway; (iii) HCV circulates in
blood associated with lipoproteins forming so-called lipoviropar-
ticles; (iv) the latter ones bind to hepatocytes via interaction,
among others, with the low-density lipoprotein (LDL) receptor [13].
Although HCV alters the host lipid metabolism to favour its
own replication and virion production, these pathophysiological
changes are shared by all viral genotypes while steatosis is more
frequent and severe in genotype 3 infection, suggesting the
involvement of additional mechanisms in case of an infectionwith
this genotype. Unfortunately, the differential efﬁciency, shown by
the various viral genotypes, in leading to the appearance of large
fat droplets has been poorly studied [10]. In addition, although
several mechanisms have been proposed to account for the viral
steatosis (for a review, see [10]), no experimental model recapit-
ulates the phenotype observed in humans. There are multiple rea-
sons for the difference between in vivo and in vitro observations:
(i) most models use hepatoma cells, (ii) the sequences used to
induce metabolic alterations, supposed to lead to steatosis, are
often derived from non-3 genotype isolates, and (iii) a direct
comparison between different genotypes has been rarely
performed, using the same model and experimental conditions.S70 Journal of Hepatology 201Finally, some claims based on evidence gathered in vitro are in
conﬂict with the observations made in humans. A typical case is
represented by the activation of transcription factors responsible
for neolipogenesis, such as SREBF1 and SREBF2. Although these
factors have been repeatedly found activated in hepatoma cells
expressing HCV proteins [14–18], oddly enough, their levels in
livers have been inversely correlated with steatosis severity
[19]. This suggests that their activation – albeit necessary for
the HCV life cycle – may not be sufﬁcient to bring about steatosis.
Clinical impact of steatosis in HCV infection
Whatever the mechanism, viral steatosis does not seem to impact
liver ﬁbrosis progression rate [20], although HCV genotype 3 is
independently associated with increased ﬁbrosis progression
[20,21]. Viral steatosis does not impair response to interferon-a
(IFN-a) [22,23]. Alternatively, steatosis due to the metabolic syn-
drome is associated with both accelerated ﬁbrosis progression
[24,25] and poor response to IFN-a-based therapy [22,23]. A dis-
tinct issue is the association between steatosis and hepatocellular
carcinoma (HCC). Several studies have associated steatosis and
the risk for HCC in chronic hepatitis C [26–28]. Due to the paucity
of patients with HCV genotype 3 included in these studies, mak-
ing any inference about a causal link between viral steatosis and
HCC is problematic. More likely, this association may have been
accounted for by the known relationship between overweight
(leading to steatosis) and HCC [29]. On the other hand, HCV geno-
type 3 infection is indeed associated with an increased risk for
HCC [21,30,31], but whether this is due to viral steatosis is
unknown. Association does not imply causation and, besides, ste-
atosis is often reduced or absent in late stages of liver disease, i.e.,
at the time HCC occurs [32–34]. Thus, evidence supporting the
argument that viral steatosis directly leads to HCC is lacking.
Some patients with genotype 3 may present a deregulation of
intracellular pathways leading to both steatosis and HCC: poten-
tial culprits include the production of reactive oxygen species
[35] or the downregulation of the tumour suppressor PTEN [36].
Viral vs. metabolic steatosis
Based on the discussion above, it seems important, from the
prognostic point of view, to distinguish viral steatosis from stea-
tosis of a different origin, especially metabolic (Table 1). Unfortu-
nately, viral steatosis does not present clear-cut histopathological
features allowing to differentiate it from steatosis due to other
causes. Thus, the differential diagnosis must rely on the history,
the presence of risk factors, serum biochemistry assays and
responsiveness to antivirals. HCV infected patients tend to have
lower levels of circulating components of lipoproteins, such as
cholesterol [25,37], especially in patients with genotype 3 [37].
This peculiar lipid proﬁle is reverted after successful therapy
[37,38], but a precise correlation between hypocholesterolemia
and steatosis has rarely been reported [23].
Both HCV and the metabolic syndrome are frequent disorders,
hence there is the probability of overlap. Non-alcoholic fatty liver
disease (NAFLD) is the liver manifestation of the metabolic syn-
drome. The occurrence and signiﬁcance of NAFLD and – more
importantly – non-alcoholic steatohepatitis (NASH) in HCV infec-
tion have rarely been studied. In an important work, the features
of patients with hepatitis C and NASH were analysed in detail
[39]. Patients with chronic hepatitis C and NASH had higher4 vol. 61 j S69–S78
Table 1. Viral vs. metabolic steatosis: clinical impact.
Viral 
steatosis
Metabolic 
steatosis
Reduced response to IFN-
Accelerated fibrosis progression
α NO YES
NO YES
Increased risk of HCC Not studied 
but likely
YES
Increased risk of atherosclerosis Not studied YES
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JOURNAL OF HEPATOLOGYsteatosis and ﬁbrosis scores, higher triglyceride levels and lower
total and high density lipoprotein cholesterol levels than those
with steatosis alone. Interestingly, they were more often infected
with genotype 3. The authors concluded that patients with
chronic hepatitis C and NASH are a distinct category of patients
with more aggressive liver disease. Importantly, NASH seemed
more common in genotype 3, where it lacked some of its typical
features such as increased insulin resistance compared to
patients with simple steatosis. The mechanisms underlying these
peculiar patterns are unknown. However, clinicians and patholo-
gists alike should be alerted by histopathological features sug-
gesting NASH – typically the presence of hepatocyte ballooning
– even when chronic hepatitis C patients present with genotype
3 and massive steatosis that may hastily be interpreted as purely
viral.HCV and glucose metabolism disturbances
HCV alters glucose homeostasis
In a meta-analysis, White and collaborators showed that HCV
infection is associated with an increased risk of type 2 diabetes
in comparison to both uninfected and hepatitis B virus (HBV)-
infected controls [40]. Among the numerous studies on this topic,
the landmark cross-sectional, general population-based study by
Mehta and collaborators, showed that HCV is associated with
type 2 diabetes among persons aged 40 years or older [41].
Longitudinal studies in immunocompetent persons and in
patients having undergone liver or kidney transplantation have
further conﬁrmed that HCV is a major risk factor for incident
type 2 diabetes, especially in persons at risk due to obesity or age
[42–47]. HCV infection precedes diabetes [48], rather than being
an iatrogenic infection in highly medicalised diabetic patients.
Overall, HCV infection seems to accelerate the occurrence of type
2 diabetes in predisposed individuals: in immunocompetent
persons, this seems to occur at least a decade earlier compared
to uninfected controls [41].
The mechanism whereby HCV induces diabetes is insulin
resistance (IR). Patients with hepatitis C have signiﬁcantly higher
levels of IR (measured by the homeostasis model for assessment
of IR [HOMA-IR]) compared to uninfected controls [49] or
patients with chronic hepatitis B matched for other risk factors
of IR, such as BMI, waist circumference, age, and sex [50]. The
methods to measure IR vary, and the observations made in
HCV-infected persons are conﬂicting depending on the technique
used. Measuring the HOMA-IR to assess IR (deﬁned by an arbi-
trary threshold of 2) [51] is very convenient when large study
populations are to be evaluated, but it seems to overestimateJournal of Hepatology 201the proportion of patients with IR, as post-load IR and stimulation
assays [52,53] have suggested a lower prevalence and level of IR.
However, the occurrence of IR in chronic hepatitis C patients
without stigmata of the metabolic syndrome has been reliably
conﬁrmed using the euglycemic hyperinsulinemic clampmethod,
an otherwise laborious technique not suitable for routine diag-
nostic use [54,55]. These studies have also shown that different
viral genotypes have comparable levels of both hepatic [52,54]
and extrahepatic [54] IR.
Direct and indirect mechanisms of HCV-associated insulin resistance
In experimental models, HCV was shown to impair the hepato-
cyte insulin signalling pathway by a variety of postreceptorial
mechanisms [56]. The central target of HCV appears to be the
protein kinase B (PKB) or Akt, whose phosphorylation is impaired
upon insulin stimulation [57]. On the other hand, in vitro
experiments have shown that basal Akt phosphorylation is
already elevated following HCV protein expression [14,58], a
possible mechanism for promoting cell survival and protection
from apoptosis [59,60]. Should this be the case in vivo, the basal
activation of Akt may lead to infected cells, refractory to further
insulin-mediated stimulation: whether we should redeﬁne the
HCV-induced IR more appropriately as a state of insulin refracto-
riness warrants further study.
Although HCV infects essentially the liver, a signiﬁcant pro-
portion of whole body IR in chronic hepatitis C patients without
features of the metabolic syndrome originates from extrahepatic
sites. Using a combination of euglycemic hyperinsulinemic clamp
technique and calorimetry, two teams independently observed a
reduced oxidative glucose consumption, secondary to a reduced
capacity to take up glucose upon insulin stimulation [54,55]. This
suggests that HCV infected hepatocytes may secrete mediators
capable of endocrine effects at extrahepatic sites, notably the
skeletal muscle.
Clinical impact of insulin resistance and diabetes in HCV infection
In chronic hepatitis C patients, IR and type 2 diabetes are major
disease modiﬁers. They are in fact associated with several poor
outcomes, including accelerated hepatic ﬁbrosis progression,
reduced SVR rates, the development of HCC, and some
cardiovascular events such as stroke [61]. As mentioned above,
steatosis – notably when due to metabolic changes, rather than
viral replication – is associated with ﬁbrosis [22]. In a retrospec-
tive study on serial liver biopsies from 135 chronic hepatitis C
patients followed for a median of 61 months, the severity of
steatosis at baseline (mostly metabolic, as 84% of patients had
HCV non-3 genotypes) predicted the ﬁbrosis progression [25].
Since metabolic steatosis is largely due to IR, the same associ-
ation exists for IR. Among 121 chronic hepatitis C patients with
minimal or no ﬁbrosis, the HOMA-IR score (but not steatosis)
was independently associated with ﬁbrosis stage and progression
rate [49]. IR and diabetes were further conﬁrmed as being associ-
ated with ﬁbrosis stage and progression in a variety of studies
[11,62–65]. The ﬁbrous tissue deposition and ﬁbrosis progression
in insulin resistant patients may be mediated by insulin itself,
which can directly stimulate hepatic stellate cells to produce
and secrete connective tissue growth factor [66]. On the other
hand, the chronic inﬂammatory state associated with the meta-
bolic syndrome involves the upregulation of pro-inﬂammatory4 vol. 61 j S69–S78 S71
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and downregulation of anti-inﬂammatory mediators [67]. Several
substances secreted by adipocytes and macrophages inﬁltrating
omental (but not subcutaneous) adipose tissue may induce
inﬂammation, ﬁbrosis deposition and, incidentally, also steatosis
in hepatic tissue [68–70], contributing to the damage linked to
hyperinsulinemia. These factors include interleukin-6, tumour
necrosis factor-a, and the monocyte chemotactic protein-1 (also
known as chemokine [C-C motif] ligand 2 or CCL2). The important
role of CCL2 is suggested not only by experimental models
[71,72], but also by the observation that increased CCL2 levels
in chronic hepatitis C patients predict liver ﬁbrosis progression
[73]. Thus, hyperinsulinemia (caused by the metabolic syndrome
and HCV) and the chronic inﬂammatory state (again, caused by
the metabolic syndrome and very likely also HCV) contribute
synergistically to liver damage severity and progression. How-
ever, it has to be mentioned that viral IR does not contribute to
steatosis, as it is speciﬁcally associated with a derangement of
glucose rather than lipid homeostasis [54].
Higher HOMA-IR scores are associated with lower SVR rates in
patients treated with IFN-a-based regimens, independently of
HCV genotypes [51,73–76]. However, a direct causal link
between IR and IFN-a resistance seems improbable, since correc-
tion of IR with pioglitazone does not inﬂuence HCV RNA levels or
virological response to therapy [77]. Treatment with metformin
seems to affect early virological response to IFN-a [78] but these
promising results have still to be independently replicated. The
negative association between IR and virological response is atten-
uated or disappears in patients treated with regimens containing
direct acting antivirals, such as telaprevir [79,80]. Danoprevir
monotherapy showed that the HOMA-IR decrease mostly paral-
leled the HCV RNA decline, and that baseline HOMA-IR levels
did not affect response [81]. It is likely that IR will not inﬂuence
the virological response to the upcoming IFN-free regimens.
Type 2 diabetes is deﬁnitely an important risk factor for HCC
development. In a prospective series on 541 chronic hepatitis C
patients [82], with Ishak ﬁbrosis scores of 4–6 (16% with diabetes
at baseline), the 5-year incidence of HCC was 5.0% in patients
without diabetes and 11.4% in those with diabetes. By multivar-
iate Cox regression analysis, diabetes was independently associ-
ated with HCC in patients with an Ishak ﬁbrosis score of 6 (HR
3.28, 95% CI 1.35–7.97). A subsequent large retrospective study
[83] showed that in chronic hepatitis C, the presence of type 2
diabetes increases the incidence of HCC nearly two-fold com-
pared with non-diabetic patients.Management of glucose metabolism alterations in hepatitis C
If HCV alters glucose metabolism, curing HCV should result in the
improvement of such disorders and into a decreased incidence of
type 2 diabetes in patients at risk. Most reports, with some excep-
tions [84], have indeed shown that SVR is associated with an
improved IR [51], and a reduced risk of incident IR [85] or other
glucose metabolism disturbances, including type 2 diabetes
[86,87]. A large study on 2842 chronic hepatitis C patients treated
with various IFN-containing regimens showed that viral eradica-
tion caused a two-thirds reduction in the risk of incident type 2
diabetes, independently of age, presence of cirrhosis and of pre-
diabetes before therapy [87]. In addition, treatment of HCV may
also reduce the risk of diabetes complications, such as renal dis-
orders and stroke, as shown by a large population-based study
from Taiwan [61].S72 Journal of Hepatology 201Nevertheless, eradication of HCV in patients with the meta-
bolic syndrome should not prevent proper management of IR
and type 2 diabetes via life-style changes and speciﬁc drugs.
Increased physical activity may reduce IR and other features of
the metabolic syndrome [88]. Interestingly, in patients with
NAFLD, even moderate- and low-intensity intervention programs
improved their metabolic proﬁle independently of body weight
changes [89]. On the other hand, a more intensive program of
body weight reduction and physical exercise was able to decrease
liver steatosis and ﬁbrosis scores in a small cohort of patients
[90]. Finally, anti-diabetic drugs may reduce some liver-related
outcomes. This beneﬁcial effect has been reported for metformin,
which has been shown to reduce signiﬁcantly (by about 50%) the
risk of developing HCC [91–94]. An optimal control of glycaemia
is pivotal in reducing this risk, since the incidence of HCC was sig-
niﬁcantly higher in patients with glycosylated haemoglobinP7%
than in those with levels <7% [83].Is HCV a cardiovascular risk factor?
Evidence that HCV infection is associated with atherosclerosis
Despite its association with IR, diabetes and steatosis, whether
HCV is an independent risk factor also for cardiovascular disor-
ders remains controversial. Since this association has been the
focus of major interest but also of some contradictory ﬁndings,
it will be discussed in further detail.
Early studies evaluated surrogate markers of cardiovascular
outcomes, such as arterial intima-media thickness (IMT) and
the presence of atherosclerotic plaques. These studies were
prompted by the frequent observations that several bacterial
[95] and viral infections [96] were associated with an increased
risk of cardiovascular and cerebrovascular diseases. Kiechl et al.
[95] reported the results of a 5-year prospective study on 826
persons, divided into those with a chronic infection (respiratory,
urinary and others) and controls. As many as 40% incident athero-
sclerotic plaques were attributed to chronic infections, especially
by Chlamydophila pneumoniae. These observations led to the
hypothesis that chronic infections may favour the atherogenic
process by inducing a systemic inﬂammatory state.
The ﬁrst case-control study focusing on HCV infection ana-
lysed 4784 individuals, 104 (2.2%) of which were anti-HCV-posi-
tive. After adjustment for confounding risk factors, the presence
of anti-HCV was associated with an increased risk of carotid-
artery plaque (OR 1.92 [95% CI 1.56–2.38]) and carotid IMT (OR
2.85 [2.28–3.57]) [97]. A second case-control study from the
same authors evaluated 1992 patients, of whom 496 had carotid
artery plaques. Although only a minority (25, i.e., 1.3%) had circu-
lating HCV core protein, this marker was a strong independent
predictor of carotid plaques [98]. Tomiyama et al. [99] conﬁrmed
these ﬁndings measuring the pulse-wave velocity in 7514 sub-
jects, and comparing results among patients with HBV, those
with anti-HCV and uninfected controls. The association between
pulse-wave velocity and HCV (but not with HBV) was indepen-
dent from atherosclerotic risk factors. Targher et al. [100] further
extended these observations by studying the carotid IMT in 60
patients with NASH, 60 with HCV, 35 with HBV, and 60 healthy
controls, comparable for age and sex. These authors observed a
gradient of thickness increasing from controls to HBV-infected
to HCV-infected and ﬁnally to NASH patients. Interestingly,
adjustments for age, sex, body mass index, smoking, LDL4 vol. 61 j S69–S78
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cholesterol, HOMA-IR and metabolic syndrome did not change
the conclusions. Although conﬁrming the association with HCV,
the results regarding HBV are at odds with current data, where
HBV is associated with a reduced prevalence of the metabolic
syndrome compared to the general population [101,102]. Targher
et al. also suggested that, if atherosclerotic changes are indepen-
dent of classical risk factors, their pathogenesis may be due to
either oxidative stress or systemic inﬂammation induced by the
viral infection.
The role of inﬂammation was further suggested by a subse-
quent study [103], where IMT and carotid plaques were assessed
in 174 chronic hepatitis C patients and 174 controls, attending an
outpatient cardiology unit. Here, the independent factors associ-
ated with carotid plaques were older age and severe liver ﬁbrosis,
leading the authors to conclude that patients with chronic
hepatitis C and severe ﬁbrosis should be screened for early
atherosclerosis independently of their age.
Finally, Adinolﬁ et al. [9] not only conﬁrmed the atheroscle-
rotic risk in young HCV-infected persons but also noted an asso-
ciation between carotid atherosclerosis and both steatosis and
viral load, hinting to a dose-effect mechanism. In the setting of
coinfection with HIV, the independent, pro-atherogenic role of
HCV seems diluted by the presence of several confounders, and
therefore the results are not univocal [104–106].HCV and cardiac disorders
Subsequent work assessed the relationship between HCV infec-
tion and some speciﬁc cardiovascular outcomes associated with
atherosclerosis. Coronary artery disease was evaluated in a
case-control study on 491 patients and 195 controls hospitalized
for other cardiac abnormalities but with normal coronary arter-
ies. The HCV prevalence was signiﬁcantly higher among patients
than among controls (6.3% vs. 2%), and increased with the num-
ber of arteries affected [107]. By multivariate analysis, HCV inde-
pendently increased the risk of coronary artery disease by a factor
of four. Similar results were reported by measuring the Reardon
score, which assesses the extent of stenosis in the proximal cor-
onary circulation [108] or in patients having undergone solid
organ transplantation [109–111]. HCV increased the risk of coro-
nary artery disease also in the observational cohort of all HCV-
infected veterans [112], including 82,083 HCV-infected and
89,582 uninfected subjects. By multivariate analysis, and despite
their favourable lipid proﬁle, HCV-infected veterans had a higher
risk of coronary artery disease (HR, 1.25; 95% CI, 1.20–1.30) on
top of classical risk factors such as age, arterial hypertension,
chronic obstructive pulmonary disease, diabetes, and hyperlipid-
emia. A similar study, using a prospective cohort design on 8579
veterans infected by HCV, coinfected by HIV and HCV, or unin-
fected [113], and followed for a median of 7.3 years, concluded
that HIV+ HCV+ veterans have an increased risk of coronary heart
disease compared with HIV+ HCV and HIV HCV veterans,
and similar conclusions were reached by Bedimo et al. [114].
Myocardial ischemia was associated with arterial hypertension,
metabolic syndrome and also HCV infection in a study conducted
on 5015 persons from Taiwan evaluated by ECG for a general
check-up [115].
Some studies have analysed the potential effect of HCV infec-
tion on heart function, rather than on the coronary artery integ-
rity. Maruyama and co-workers studied 217 HCV-infected
patients by myocardial scintigraphy and found that 87% hadJournal of Hepatology 201myocardial perfusion defects, and that the severity of the defects
was associated with the degree of liver necroinﬂammatory activ-
ity [116]. The interesting aspect of this study is that the response
to antiviral therapy was accompanied by the improvement of
anomalies, in contrast with the lack of response. However, using
data of 19,741 persons (173 or 0.88% with detectable HCV RNA)
from a general population survey [117], Younossi and co-workers
found that HCV was independently associated with IR, diabetes,
hypertension and congestive heart failure, but not with ischaemic
heart disease.
HCV and stroke
Regarding cerebrovascular outcomes, a cohort study from Taiwan
found that chronic hepatitis C is an independent predictor of
stroke [118]. As many as 4094 adults with HCV infection were
compared to 16,376 adults without HCV and matched by age
and sex. Compared with uninfected persons, the adjusted HR of
stroke was 1.27 (95% CI 1.14 to 1.41) for people with HCV.
Another community-based, prospective study found that HCV
infection is an independent predictor of cerebrovascular death,
and a signiﬁcant dose-effect association was observed between
serum HCV RNA levels and cerebrovascular mortality, suggestive
of a causal link [119]. Importantly, IFN-based therapy reduced by
60% the incidence of stroke, compared to no treatment, in
another large, retrospective cohort study [120], further adding
evidence for a causal association between HCV infection and
cerebrovascular damage. Similar results were reported more
recently in a prospective cohort study where 1411 diabetic HCV
patients treated with IFN-a-based regimens were matched with
1411 diabetic, HCV-infected but untreated controls [61]. The
treated cohort was further matched with 5644 diabetic unin-
fected controls. After 8 years of follow-up, the difference in the
cumulative incidence of end-stage renal disease and stroke
among treated, untreated, and uninfected cohorts was signiﬁcant.
In multivariate analysis, antiviral treatment was associated with
a signiﬁcantly reduced risk of end-stage renal disease (HR = 0.16;
95% CI, 0.07–0.33%) and of ischemic stroke (HR = 0.53; 95% CI,
0.30–0.93), although no data were available on the post-
treatment HCV RNA status. These impressive results need
conﬁrmation in different areas of the world, but will likely
inﬂuence the future paradigm of therapy for chronic hepatitis C
by extending it to patients at risk of extrahepatic complications,
irrespective of the severity of the underlying liver damage.
HCV and cardiovascular mortality
If HCV is implicated in the pathogenesis of cardiovascular lesions,
this should result into an increased cardiovascular mortality, as
shown by studies linking large databases with death registries.
The ﬁrst of such studies appeared in 2006 [121] and was con-
ducted on 75,834 patients with hepatitis C. In this population, car-
diovascular diseases were the third most common cause of death,
with a standardized mortality ratio of 1.3 (95% CI 1.2–1.5) after
adjustment for age, sex, and calendar year. However, no data were
available on possible confounders such as smoking. In a following
retrospective cohort study, Guiltinan and collaborators studied
10,259 anti-HCV-positive blood donors and 10,259 HCV-seroneg-
ative donors matched for age, gender and other parameters [122].
Anti-HCV-positive donors presented an increased cardiovascular
mortality (HR = 2.21, 95% CI: 1.41–3.46). Unfortunately, data for4 vol. 61 j S69–S78 S73
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socioeconomic status, smoking, cholesterol, diet, or other con-
founders were again missing; ethnicity data was incomplete,
and chronic cocaine use data, linked to an increased risk of coro-
nary artery calciﬁcation [123] was also missing. Finally, according
to a vast study issued by the REVEAL cohort, 23,820 adults in
Taiwan – 1095 of which were anti-HCV-positive and 760 had
detectable HCV RNA – were prospectively followed for an average
period of 16.2 years [124]. This important study showed that
persistent HCV infection increased both hepatic and extrahepatic
mortality compared to uninfected controls. In particular, anti-
HCV-positive participants had a higher risk of dying from
circulatory diseases and renal diseases, with a multivariate-
adjusted HR of 1.50 (95% CI 1.10–2.03) and 2.77 (1.49–5.15),
respectively, compared with seronegative persons. The associa-
tion between HCV RNA and cardiovascular death showed that it
is the replicating HCV rather than prior infection (i.e. seropositive
for anti-HCV but negative for HCV RNA) that matters in predicting
the risk of mortality. Furthermore, this study collected a vast array
of data from enrolled persons, allowing adjustment of hazard
ratios for age, sex, cigarette smoking, alcohol drinking, and central
obesity; hazard ratios for circulatory diseases were additionally
adjusted for personal history of diseases and baseline serum levels
of cholesterol and triglycerides. Thus, based on these two studies
from Taiwan, it seems as if treating HCV not only reduces the
liver-related outcomes, but also the extrahepatic ones.
HCV and cardiovascular lesions: in search of a mechanism
The fact that HCV seems to increase the risk of morbidity and
mortality only for some speciﬁc cardiovascular events, and the
observation that the atherogenic role of HCV appears indepen-
dent of classical risk factors, including smoking and the
metabolic syndrome, raise the issue of the pathogenesis of
cardiovascular damage in HCV infection. Although metabolic
factors, such as steatosis [9], may play a role, systemic chronic
inﬂammation seems more likely to be a central factor
[100,103,115], together with possible endothelial dysfunction
[100] and the contribution of genetic and environmental factors.
The proposal of a direct viral infection of the arterial wall [125]
has not been independently conﬁrmed, although HCV has been
shown to infect the brain endothelial cells [126]. Finally, it is
interesting to note that according to a very recent Danish study,
some biomarkers predictive of coronary artery disease were
more elevated in 60 HCV-infected patients than among 60 con-
trols: these markers included high-sensitivity C-reactive protein,
soluble intercellular adhesion molecule-1, soluble vascular cell
adhesion molecule-1 and soluble E-selectin [127]. These con-
cepts are summarized in Fig. 2. Further research is warranted
in this fascinating ﬁeld.
HCV and cardiovascular risk: a note of caution
This discussion would not be complete without mentioning the
studies that have failed to identify an association between HCV
infection and cardiovascular morbidity. A ﬁrst case-control study
from the northeast of Germany (Pomerania) [128] enrolled 233
cases with antibody to HCV or HBV surface antigen (anti-HBs),
and 4033 seronegative controls. By multivariate analysis, there
was no association between serostatus and myocardial infarction,
stroke, carotid IMT, and carotid plaques. However, this study
pooled patients with HCV infection together with those curedS74 Journal of Hepatology 201from HBV infection, and this may have diluted any effect due to
HCV. On the other hand, a mere 21 patients were anti-HCV-posi-
tive. Similarly, a case-control study of 292 active-duty US military
personnel hospitalized for acute myocardial infarction and 290
controls failed to ﬁnd an association between HCV and acute
myocardial infarction [129]. Although only 52 cases were anti-
HCV-positive, the results were clearly arguing against a putative
role of HCV in inducing myocardial infarction.
A subsequent 5-year longitudinal case-control study (40
HCV-infected patients and 40 uninfected controls, matched for
classical atherosclerotic risk factors) analysed the progression
of atherosclerotic plaques in carotid and femoral arteries [130].
Not only patients showed no changes in plaque and IMT during
follow-up, but a signiﬁcant increase in carotid IMT was observed
only among controls, prompting the authors to suggest that HCV
may even delay the atherosclerotic process, possibly via its
favourable lipid proﬁle. Another large prospective cohort study
from Norway on 1010 HCV-positive patients followed for a
median of 7 years [131] failed to show a statistically signiﬁcant
increase in the standardized mortality ratio due to cardiovascu-
lar diseases. However, data on smoking and other cardiovascular
risk factors were missing. In addition, the diagnostic assays for
HCV were performed by occasional blood testing, and therefore
the number of HCV-related deaths may have been underesti-
mated. Finally, a large retrospective cohort study conducted in
the UK enrolled 4809 HCV-infected individuals matched for
age, sex and medical practice with up to 15 randomly selected
patients without HCV, leading to a staggering number of
71,668 controls [132]. Rates of incident MI during a median fol-
low-up of 3.2 years were comparable between HCV-infected and
uninfected cases.
The discrepancies between the numerous studies reported
above have enlivened the debate regarding the association
between HCV and cardiovascular outcomes. Large studies con-
ducted with rigour and a wealth of data have produced compel-
ling but conﬂicting results. It seems very likely that the increase
in risk for selected outcomes may be small, to the point of being
heavily conditioned by unknown confounders, including genetic
variants. The latter may explain the striking differences among
studies conducted in different ethnical populations. Only care-
fully conducted, prospective cohort studies, using appropriate
stratiﬁcations and exploiting the high efﬁcacy of novel antivirals
may discriminate the effect of HCV on each single cardiovascular
disorder.4 vol. 61 j S69–S78
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